Results 281 to 290 of about 2,210,175 (342)

Fractal Anatomy of Human Organs: A Narrative Review of Structure, Function, and Clinical Perspectives

open access: yesClinical Anatomy, EarlyView.
ABSTRACT Fractal geometry describes complex, self‐similar patterns that repeat across spatial scales and is increasingly recognized as relevant in anatomical research. Indeed, the fractal organization is consistently observed in respiratory, cardiovascular, gastrointestinal, nervous, renal, hepatic, and dermatological systems.
Immacolata Belviso   +7 more
wiley   +1 more source

Dual targeting NG2 and GD3A using Mab-Zap immunotoxin results in reduced glioma cell viability in vitro [PDF]

open access: yes, 2015
Ashkan, Keyoumars   +4 more
core   +1 more source

A Bifunctional Small Molecule Degrader of the Long Noncoding RNA MALAT1 Triplex

open access: yesChemistry – A European Journal, EarlyView.
Targeting disease‐linked RNAs with small molecules is often limited by the modest impact of binding RNA structure alone. Here, we present a first‐in‐class bifunctional molecule that degrades the oncogenic lncRNA MALAT‐1 by inducing proximity between the RNA and a cleaving warhead.
Christian A. T. Brega   +11 more
wiley   +1 more source

Non‐Syndromic Tumefactive Demyelinating Lesions in the Pediatric Population: Four Case Reports and Review of the Literature

open access: yesAnnals of the Child Neurology Society, EarlyView.
ABSTRACT Introduction Tumefactive demyelinating lesions (TDLs) are large lesions (> 2 cm) seen in demyelinating syndromes such as multiple sclerosis, myelin oligodendrocyte glycoprotein antibody‐associated disorder, and neuromyelitis optica spectrum disorder. They rarely occur in children and most often have a monophasic course.
Elizabeth C. Ballinger   +6 more
wiley   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy